Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Receivables (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Change in Receivables for 9 consecutive years, with $649850.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 165.84% year-over-year to $649850.0, compared with a TTM value of $1.2 million through Sep 2025, down 34.64%, and an annual FY2024 reading of $2.3 million, up 293.54% over the prior year.
  • Change in Receivables was $649850.0 for Q3 2025 at Sunshine Biopharma, up from -$65711.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.8 million in Q2 2024 and bottomed at -$986986.0 in Q3 2024.
  • Average Change in Receivables over 5 years is $212951.2, with a median of $6669.0 recorded in 2021.
  • The sharpest move saw Change in Receivables surged 3166200.0% in 2023, then plummeted 1658.68% in 2024.
  • Year by year, Change in Receivables stood at $6669.0 in 2021, then soared by 7881.14% to $532262.0 in 2022, then decreased by 10.63% to $475659.0 in 2023, then skyrocketed by 113.81% to $1.0 million in 2024, then plummeted by 36.1% to $649850.0 in 2025.
  • Business Quant data shows Change in Receivables for SBFM at $649850.0 in Q3 2025, -$65711.0 in Q2 2025, and -$426673.0 in Q1 2025.